Get the Stockscreener App
53.57
3.20%
1.66
After Hours:
53.57
Biomarin Pharmaceutical Inc stock is traded at $53.57, with a volume of 3.25M.
It is up +3.20% in the last 24 hours and down -1.09% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$51.91
Open:
$51.33
24h Volume:
3.25M
Relative Volume:
1.36
Market Cap:
$10.29B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
19.91
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-1.67%
1M Performance:
-1.09%
6M Performance:
-15.89%
1Y Performance:
-18.70%
1-Day Range:
$51.00
$53.62
1-Week Range:
$51.00
$56.80
52-Week Range:
$51.00
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.57 | 9.97B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap by valuation metricsQuarterly Earnings Report & Reliable Volume Spike Trade Alerts - newser.com
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsJuly 2025 Outlook & Free Technical Pattern Based Buy Signals - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecastsEarnings Risk Report & Verified Trade Idea Suggestions - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
What is William Blair's Estimate for BMRN Q4 Earnings? - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 14,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetOptions Play & Weekly Return Optimization Plans - newser.com
Why BioMarin Pharmaceutical Inc. stock is in analyst buy zoneWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as Shares Recover 3% After Prolonged Downtrend - Sahm
How to monitor BioMarin Pharmaceutical Inc. with trend dashboards2025 Valuation Update & High Yield Stock Recommendations - newser.com
10 Best Beaten Down Growth Stocks to Buy According to Analysts - Insider Monkey
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Cantor Fitzgerald Has Negative View of BMRN FY2025 Earnings - MarketBeat
How currency fluctuations impact BioMarin Pharmaceutical Inc. stock2025 Technical Overview & Safe Swing Trade Setups - newser.com
How to read the order book for BioMarin Pharmaceutical Inc.Market Activity Report & Daily Profit Focused Stock Screening - newser.com
Sentiment analysis tools applied to BioMarin Pharmaceutical Inc.Global Markets & AI Enhanced Trading Alerts - newser.com
BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 - Insider Monkey
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
BioMarin Pharmaceutical Inc. Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD By Investing.com - Investing.com South Africa
After a futile battle, Biomarin will sell the bleeding disorder drug Roctavian - medwatch.com
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD - Investing.com
Cantor Fitzgerald Issues Negative Forecast for BMRN Earnings - MarketBeat
BioMarin Pharma plans to divest struggling gene therapy - MSN
Results: BioMarin Pharmaceutical Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - 富途牛牛
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Wedbush - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company - MarketBeat
Stifel Nicolaus Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $73.00 - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $80.00 at Barclays - MarketBeat
BioMarin (NASDAQ: BMRN) PALYNZIQ sBLA gets FDA Priority Review to expand to ages 12–17 - Stock Titan
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Morgan Stanley Lowers BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $98.00 - MarketBeat
Teacher Retirement System of Texas Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Asset Management One Co. Ltd. Has $4.84 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):